Schrödinger

Learning Objectives

• Understand Schrödinger's role in physics-based + AI drug discovery
• Identify the platform's combination of established physics simulation with newer ML
• Evaluate when Schrödinger fits a research workflow vs pure-AI competitors

What Is Schrödinger?

Schrödinger is the computational platform combining physics-based simulation and machine learning for drug discovery and materials science. Founded in 1990, Schrödinger predates the AI biotech wave by decades — its physics-based methods (molecular dynamics, free-energy perturbation, quantum mechanics) have been used across pharmaceutical R&D for over 30 years. The company has progressively augmented physics-based methods with machine learning to accelerate computation while preserving physical accuracy.

The strategic significance: Schrödinger's physics + ML hybrid approach is now the foundation infrastructure for many newer AI biotech companies. Manas AI's January 2026 strategic agreement with Schrödinger granted significant access to Schrödinger's physics-based computational platform — a meaningful capability multiplier for newer AI drug discovery startups that don't want to rebuild physics simulation infrastructure.

Pricing & Customer Base

Schrödinger uses tiered enterprise pricing for pharmaceutical and biotech customers.

Schrödinger's revenue mixes software licensing with drug-discovery partnerships and internal pipeline economics — public-listed (SDGR ticker).

Core Capabilities

Physics-Based Molecular Simulation

The foundation. Free-energy perturbation (FEP), molecular dynamics (MD), quantum mechanics (QM) — physics-grounded simulation of molecular behavior. Predicts how molecules bind to targets, behave in solution, and interact with biological systems based on first-principles physics.

Machine Learning Augmentation

Machine learning accelerates physics-based simulation without sacrificing accuracy:

• ML-augmented FEP — faster binding affinity prediction
• ML-driven molecular property prediction — ADMET (Absorption, Distribution, Metabolism, Excretion, Toxicity)
• ML-guided molecule generation — proposing candidates that physics simulation can then validate

Drug Discovery Platform

Schrödinger's drug discovery applications cover the full small-molecule R&D workflow:

• Target validation
• Lead identification
• Lead optimization
• ADMET property prediction
• Crystal structure prediction

Materials Science

Beyond drug discovery, Schrödinger applies the same physics + ML methods to materials science — battery materials, photovoltaic materials, catalysts, polymers. Diverse industries beyond pharmaceuticals.

Manas AI Partnership (January 2026)

A major recent development. Manas AI's January 2026 strategic agreement with Schrödinger grants Manas significant access to Schrödinger's physics-based computational platform. This is one example of a broader pattern: newer AI drug discovery companies leveraging Schrödinger's mature physics infrastructure rather than rebuilding from scratch.

Bunsen: Agentic AI Co-Scientist (July 2026)

Schrödinger's newest product. Bunsen is an agentic AI co-scientist that helps researchers understand a scientific objective, plan a computational strategy, run the molecular discovery workflows and interpret the results, all on Schrödinger's validated physics-based platform. It launched in early access for select customers, with NVIDIA and Google Cloud supplying compute for early users, and Schrödinger has not published pricing. In August 2026 Bristol Myers Squibb agreed to deploy Bunsen across its research organization.

Bunsen is an AI layer on top of the physics engine, not a replacement for it. The machine learning plans and interprets; the simulations it runs are the same free-energy and molecular-dynamics methods the platform was built on.

Internal Drug Pipeline

Schrödinger develops its own drug candidates — partnered or wholly-owned — through clinical stages. Multiple programs across diverse therapeutic areas. Validates the platform commercially.

Public Company (SDGR)

Schrödinger is public-listed under SDGR — providing investor transparency and substantial capital for R&D. Quarterly earnings reflect both software revenue and drug-discovery progress.

Strengths

• 30+ year track record: Established physics methods predate AI biotech wave
• Physics + ML hybrid: Physical accuracy + ML acceleration
• Drug discovery + materials science: Diverse industries
• Manas AI partnership precedent: Newer AI biotech leveraging Schrödinger
• Bunsen agentic co-scientist: AI that plans and runs physics workflows, adopted by Bristol Myers Squibb
• Internal drug pipeline: Commercial validation
• Public-listed scale: SDGR ticker; substantial R&D capital
• Pharma partnership track record: Established multi-year customer relationships

Limitations & Considerations

• Custom-quote pricing: Not transparent
• Software licensing complexity: Multiple modules add up at enterprise scale
• Public-company stock pressure: Quarterly earnings affect strategic flexibility
• Less novelty than newest AI biotech: Physics-grounded approach predates AlphaFold-derived methods
• Multi-decade software architecture: Some legacy patterns vs newer vendors
• Compute-intensive: Physics simulation requires substantial compute
• Specialized to molecular science: Not general-purpose AI

Best Use Cases

When to choose alternatives:

• Cutting-edge AI structure prediction → Isomorphic Labs IsoDDE (AlphaFold 4-class)
• Pure-AI drug discovery → Insilico Medicine with clinical-stage candidates
• Knowledge-graph drug discovery → BenevolentAI
• Cellular reprogramming → Altos Labs, Calico
• Generic AI biotech → not a substitute for specialized molecular simulation

Key Takeaways

• Schrödinger is the computational platform combining physics-based simulation (molecular dynamics, free-energy perturbation, quantum mechanics) and machine learning for drug discovery and materials science — founded 1990
• 30+ year track record predates the AI biotech wave; physics-grounded methods now augmented with ML for acceleration without sacrificing physical accuracy
• Bunsen, an agentic AI co-scientist that plans and runs Schrödinger's physics workflows, entered early access in July 2026; Bristol Myers Squibb agreed to deploy it in August
• January 2026 Manas AI strategic agreement granting significant access to Schrödinger's physics platform exemplifies broader pattern of newer AI biotech leveraging Schrödinger's mature infrastructure
• Public-listed under SDGR with revenue mix of software licensing, drug-discovery partnerships, and internal drug pipeline progress
• Best fit for pharma drug discovery R&D, AI biotech leveraging physics infrastructure, materials science research, and lead optimization workflows; for cutting-edge structure prediction use IsoDDE; for pure-AI clinical-stage discovery use Insilico Medicine